Impact of reduced uterine perfusion pressure model of preeclampsia on metabolism of placenta, maternal and fetal hearts

Lana McClements1, Claire Richards1, Nikayla Patel2, Hao Chen1, Kimberly Sesperez1, Kristen J. Bubb3, Anja Karlstaedt4 & Dunja Aksentijevic2*

Preeclampsia is a cardiovascular pregnancy complication characterised by new onset hypertension and organ damage or intrauterine growth restriction. It is one of the leading causes of maternal and fetal mortality in pregnancy globally. Short of pre-term delivery of the fetus and placenta, treatment options are limited. Consequently, preeclampsia leads to increased cardiovascular disease risk in both mothers and offspring later in life. Here we aim to examine the impact of the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia on the maternal cardiovascular system, placental and fetal heart metabolism. The surgical RUPP model was induced in pregnant rats by applying silver clips around the aorta and uterine arteries on gestational day 14, resulting in ~40% uterine blood flow reduction. The experiment was terminated on gestational day 19 and metabolomic profile of placentae, maternal and fetal hearts analysed using high-resolution 1H NMR spectroscopy. Impairment of uterine perfusion in RUPP rats caused placental and cardiac hypoxia and a series of metabolic adaptations: altered energetics, carbohydrate, lipid and amino acid metabolism of placentae and maternal hearts. Comparatively, the fetal metabolic phenotype was mildly affected. Nevertheless, long-term effects of these changes in both mothers and the offspring should be investigated further in the future.

Cardiovascular disease is the main cause of death worldwide. Converging lines of evidence suggest that an adverse intrauterine environment precipitates maternal, placental and fetal adaptations, resulting in the developmental programming of cardiometabolic dysfunction in juvenile and adult offspring1–3. Preeclampsia is a cardiovascular pregnancy complication that occurs in 5–10% of pregnancies and is one of the leading causes of maternal and fetal morbidity and mortality worldwide4. It is associated with poor pregnancy outcomes and can lead to lifelong risk from cardiovascular complications in the offspring: an early onset of cardiac hypertrophy, aortic remodelling5–8, oxidative stress, endothelial dysfunction, hypertension, and adverse ischemia–reperfusion (IR) outcomes in adult life3. Compared to normotensive pregnancies, mothers with early-onset preeclampsia presenting prior to 34 weeks of gestation (EOPE) have increased mortality risk (up to 9–10-fold) from cardiovascular disease, whereas mothers diagnosed with late-onset preeclampsia after 34 weeks gestation (LOPE) are at a two-fold increased risk of CVD-related mortality9,10. Recently, multiple common features were recognized between preeclampsia and heart failure with preserved ejection fraction (HFpEF) including factors such as hypertrophy, angiogenesis, inflammation and haemostasis11,12. However, the exact metabolic adaptations, which may impact in utero development and may lead to cardiometabolic consequences in adult life, have not been fully elucidated. Moreover, effective therapeutic and diagnostic strategies are still missing due to the lack of mechanistic insight into the causal nexus of preeclampsia. Nevertheless, an inability of the maternal cardiovascular system to alleviate preeclampsia-induced changes appears to have a critical role in defective placental development including oxidative stress, abnormal angiogenesis and pro-inflammatory responses13.

Pre-clinical models of preeclampsia are challenging to establish, due to the presence of inter-species variations and the fact that most animals do not develop spontaneous preeclampsia14. The most reliable animal

1School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia. 2Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. 3Biomedical Discovery Institute, Monash University, Melbourne, Australia. 4Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA, 127 San Vicente Blvd, 90048. *email: d.aksentijevic@qmul.ac.uk
Reduced uterine perfusion pressure pregnancy model in rats. Time-mated pregnant Sprague–Dawley rats were purchased from the Animal Resources Centre (ARC) and were fed a standard sterile chow diet with water access ad libitum. On gestational day (GD) 14, pregnant rats were randomised to the Sham (control; n = 8) or RUPP (n = 7) procedure as previously described15,26,27. Briefly, silver clips were applied to the aorta above the iliac bifurcation (0.203 mm ID) and both the right and left uterine arcades (0.100 mm ID) to reduce blood flow to the uterus by ~ 40% in the RUPP group whereas rats in the Sham (control) group underwent a similar procedure, without clips being applied. On GD19, after clinical phenotyping was completed, rats were euthanized as per local standard operating procedures using isoflurane overdose/exsanguination followed by removal of the heart. Maternal hearts, placentae and embryo hearts were collected, weighed and snap frozen in liquid N2. All clinical phenotyping, placental and embryo data for these rats were reflective of the preeclampsia phenotype as published previously26 and reproduced here with permission (Table 1). For this study, five matching maternal hearts, placenta and fetal hearts were available from each group for downstream metabolomic analysis as described above. All animal experiments were approved by the Northern Sydney Local Health District Animal Ethics Committee (Animal Ethics number: RESP/18/317) and carried out in accordance to the Australian code for the care and use of animals for scientific purposes and ARRIVE guidelines.

|                                | Sham (n ≥ 6) | RUPP (n ≥ 4) | P value |
|--------------------------------|-------------|--------------|---------|
| Maternal body weight (before surgery), g | 338.6 ± 17.5 | 379.5 ± 4.87 | 0.084   |
| Maternal heart weight, g         | 1.02 ± 0.05  | 1.22 ± 0.01  | **0.008** |
| Heart: Body weight, %            | 0.304 ± 0.01 | 0.323 ± 0.005 | 0.303   |
| Embryo resorption (%)            | 2.38 ± 1.51  | 11.22 ± 3.06 | 0.04*   |
| Embryo weight, g                 | 1.68 ± 0.025 | 1.61 ± 0.02  | 0.04    |
| Placental weight, g              | 0.41 ± 0.009 | 0.39 ± 0.006 | 0.047   |
| Heart rate, bpm                  | 369.3 ± 4.8  | 398.8 ± 3.7  | ***0.0006*** |
| Systolic BP, mmHg                | 112.6 ± 1.3  | 127.8 ± 1.9  | <0.0001*** |
| Diastolic BP, mmHg               | 87.6 ± 1.7   | 104.0 ± 1.8  | <0.0001*** |
| MABP, mmHg                       | 100.9 ± 1.5  | 116.7 ± 1.7  | <0.0001*** |
| Stroke volume, µl                | 215.0 ± 4.326| 230.0 ± 13.26| 0.304   |
| Cardiac output, mL/min           | 79 ± 3       | 85 ± 5       | 0.067   |
| Ejection fraction, %             | 82 ± 2       | 78 ± 2       | 0.233   |
| Fractional shortening, %         | 52 ± 2       | 49 ± 2       | 0.236   |
| Corrected LV mass, mg            | 600 ± 14     | 706 ± 68     | 0.037*  |
| LV anterior wall systolic, mm    | 2.9 ± 0.12   | 2.9 ± 0.11   | 0.672   |
| LV anterior wall diastolic, mm   | 1.5 ± 0.04   | 1.8 ± 0.17   | 0.152   |
| LV posterior wall systolic, mm   | 2.8 ± 0.14   | 2.9 ± 0.09   | 0.303   |
| LV posterior wall diastolic, mm  | 1.6 ± 0.05   | 1.6 ± 0.11   | 0.994   |

Table 1. Morphological features and cardiac function characteristics of the RUPP model (maternal and fetal). Unpaired Student’s t-test or Mann–Whitney test were used depending on data distribution. This figure was originally published in Biology of Sex Differences and used with permission26 (https://doi.org/10.1186/s13293-021-00376-1). BP blood pressure, LV left ventricular, MABP mean arterial blood pressure, RUPP reduced uterine perfusion pressure. *P < 0.05, **P < 0.01, ***P < 0.001

Model of preeclampsia is the surgically-induced reduced uterine perfusion pressure (RUPP) model. This model has been shown to induce hypertension15, proteinuria15, renal dysfunction15,16, an anti-angiogenic state17, inflammation18–20, vasoconstriction21, oxidative stress22, cardiac dysfunction23 and intrauterine growth restriction (IUGR)24,25 like that of preeclampsia in humans.

We have also recently shown in this model increased cardiac expression of the anti-angiogenic protein, FKBPL, and the presence of placental and cardiac fibrosis26. Given the significant association between preeclampsia and CVD, a more thorough investigation of cardiac health in the RUPP model is required. In this study, we demonstrate in the RUPP rat model of preeclampsia, the presence of cardiovascular and metabolic remodelling of maternal heart and placenta. We also show that the series of functional and metabolic maternal adaptations to early restricted angiogenesis precede metabolic alterations in the fetal heart.

Methods

Reduced uterine perfusion pressure pregnancy model in rats. Time-mated pregnant Sprague–Dawley rats were purchased from the Animal Resources Centre (ARC) and were fed a standard sterile chow diet with water access ad libitum. On gestational day (GD) 14, pregnant rats were randomised to the Sham (control; n ≥ 6) or RUPP (n ≥ 4) procedure as previously described15,26,27. Briefly, silver clips were applied to the aorta above the iliac bifurcation (0.203 mm ID) and both the right and left uterine arcades (0.100 mm ID) to reduce the blood flow to the uterus by ~ 40% in the RUPP group whereas rats in the Sham (control) group underwent a similar procedure, without clips being applied. On GD19, after clinical phenotyping was completed, rats were euthanized as per local standard operating procedures using isoflurane overdose/exsanguination followed by removal of the heart. Maternal hearts, placentae and embryo hearts were collected, weighed and snap frozen in liquid N2. All clinical phenotyping, placental and embryo data for these rats were reflective of the preeclampsia phenotype as published previously26 and reproduced here with permission (Table 1). For this study, five matching maternal hearts, placenta and fetal hearts were available from each group for downstream metabolomic analysis as described above. All animal experiments were approved by the Northern Sydney Local Health District Animal Ethics Committee (Animal Ethics number: RESP/18/317) and carried out in accordance to the Australian code for the care and use of animals for scientific purposes and ARRIVE guidelines.

1H Nuclear magnetic resonance spectroscopy metabolomic profiling. Frozen, weighed and pulverized hearts (fetal and maternal) and placenta were subjected to methanol/water/chloroform dual-phase extraction28. The aqueous upper phase was separated from the chloroform and protein fractions. 30 mg chelex-100 was added to chelate paramagnetic ions, vortexed and centrifuged at 3600 RPM for 5 min at 4 °C. The supernatant was added to a fresh Falcon tube containing 10 µL universal pH indicator solution followed by vortexing and lyophilisation. Dual-phase-extracted metabolites were reconstituted in 600 µL deuterium oxide (containing 8 g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HP04, 0.2 g/L KH2PO4 and 0.0075% w/v trimethylsilyl propanoic acid (TSP)) and adjusted to pH = 6.5 using 1 M hydrochloric acid and/or 1 M sodium hydroxide28.
Samples were analysed using a vertical-bore, ultra-shielded Bruker 14.1 T (600 MHz) spectrometer with a bbo probe at 303 K. Spectra were acquired with the Bruker nesyqpp1d pulse sequence with 128 scans, 4 dummy scans and 20 ppm sweep width, acquisition time of 2.6 s, pre-scan delay of 4 s, 90° flip angle and experiment duration of 14.4 min. TopSpin (version 4.0.5) software was used for data acquisition and for metabolite quantification. FIDs were multiplied by a line broadening factor of 0.3 Hz and Fourier-transformed, phase and automatic baseline-correction were applied. Chemical shifts were normalized by setting the TSP signal to 0 ppm. In terms of glycogen quantification, given that it is a large macromolecule containing multiple glucose monomers, we measured a number of mobile 1H in the glucose monomers that are present in the NMR peak, normalized to the reference.

Peaks of interest were integrated automatically using a pre-written integration region text file and then manually adjusted where required. Assignment of metabolites to their respective peaks was carried out based on previously obtained in-house data, confirmed by chemical shift and using Chenomx NMR Profiler Version 8.1 (Chenomx, Canada). Peak areas were normalized to the TSP peaks and metabolite concentrations were quantified per gram tissue wet weight.

### Metabolic network analysis of placenta

Given that the most extensive metabolite concentration changes were identified in placenta (>2 metabolites), network plots of metabolite co-regulation were generated with the igraph package in R programming language (4.1.0). Each node was representative of a significantly different metabolite from different tissues in RUPP mice compared to the sham controls. Only the strongly correlated nodes were shown (absolute Pearson correlation coefficient |r| > 0.7), and colour of each edge was indicative of Pearson r. The functional classifications of nodes were annotated as the colour of nodes. Each node was sized proportionally to the epigenvector centrality (the importance of the network).

### In Silico modelling

In silico simulations (maternal hearts) were conducted using the metabolic network of the cardiomyocyte CardioNet31,32 as described in the Supplementary Information. Details of all reactions and their metabolic subsystems were annotated based on the Kyoto Encyclopedia of Genes and Genomes database.

### Statistical analysis

Statistical analysis was performed in GraphPad Prism (v9). Normality of data distribution was examined using Shapiro–Wilk’s normality test. Sham and RUPP groups were compared using the unpaired student’s t-test (normally distributed data) and Mann–Whitney U test (non-normally distributed data) with statistically significant results equivalent to a p-value of 0.05 or less.

### Results

The pre-clinical rat model of preeclampsia resulting from the RUPP surgical intervention on gestational day 14 led to a series of maternal and fetal physiological adaptations (Table 1). We have recently shown that the RUPP procedure leads to reduced placenta and fetal weight as well as increased fetal resorption (Table 1). Furthermore, it triggers cardiac and placental fibrosis, maternal haemodynamic overload resulting in increased heart rate, systolic, diastolic and mean arterial pressures collectively resulting in increased LV mass and cardiac hypertrophy indicative of diastolic dysfunction (Table 1). However, there was no evidence of maternal cardiac failure as in vivo cardiac function parameters including ejection fraction, cardiac output and stroke volume were comparable to sham controls. These observations are collectively reflective of preeclampsia in humans. Furthermore, RUPP intervention leads to placental hypoxia indicated by increased in hypoxia inducible factor (HIF)-1α protein expression (Fig. 1; P < 0.05). However, there were no changes in the mRNA expression of the inflammation marker galactin-3 in maternal tissues (placenta and heart, Supplementary Fig. S1).

### RUPP impact on placental, maternal and fetal cardiac metabolism

Using high resolution 1H NMR spectroscopy (representative spectra shown in Fig. 2) we were able to identify a series of changes in the metabolomic profiles of maternal hearts, fetal hearts and placenta due to RUPP-induced preeclampsia. Metabolomic profile of maternal hearts show reduced NAD/NADH ratio indicative of an altered redox pool (Fig. 3A),...
increased glucose and glycogen levels (Fig. 3C) as well as altered lipid metabolism constituents, acetate and acetyl carnitine (Fig. 3D). Furthermore, there were decreased levels of succinate (Fig. 3B) however given that the succinate/fumarate ratio was unaltered (Sham 26 ± 8 vs RUPP 15 ± 5, P < 0.2), the overall TCA cycle flux appears unaltered. Despite a series of changes in metabolite levels across different metabolic compartments, there is no evidence of energetic deficit or stress as creatine reserve and PCr/ATP ratio are comparable to sham controls. Furthermore, there is no change in the total adenine nucleotide (TAN) pool as ATP, ADP and AMP levels are comparable between the groups (Fig. 3A) and no alterations in the amino acid metabolism short of aspartate (Fig. 3E). Furthermore, there is evidence that preeclampsia induced maternal cardiac hypoxia as the protein levels of HIF-1α are increased compared to the sham controls (Fig. 1B) in agreement with the altered carbohydrate pool (Fig. 3C).

Placentae of the RUPP dams developed various metabolic adaptations. The RUPP placenta is characterized by altered TAN pool and reduced PCr/ATP ratio energy reserve (Fig. 4A), without changes in the TCA cycle (Fig. 4B). Furthermore, there are alterations in carbohydrate, lipid and amino acid metabolism: enhanced glucose and glycogen levels (Fig. 3C) as well as altered lipid metabolism constituents, acetate and acetyl carnitine (Fig. 3D). Furthermore, there were decreased levels of succinate (Fig. 3B) however given that the succinate/fumarate ratio was unaltered (Sham 26 ± 8 vs RUPP 15 ± 5, P < 0.2), the overall TCA cycle flux appears unaltered. Despite a series of changes in metabolite levels across different metabolic compartments, there is no evidence of energetic deficit or stress as creatine reserve and PCr/ATP ratio are comparable to sham controls. Furthermore, there is no change in the total adenine nucleotide (TAN) pool as ATP, ADP and AMP levels are comparable between the groups (Fig. 3A) and no alterations in the amino acid metabolism short of aspartate (Fig. 3E). Furthermore, there is evidence that preeclampsia induced maternal cardiac hypoxia as the protein levels of HIF-1α are increased compared to the sham controls (Fig. 1B) in agreement with the altered carbohydrate pool (Fig. 3C).

Placentae of the RUPP dams developed various metabolic adaptations. The RUPP placenta is characterized by altered TAN pool and reduced PCr/ATP ratio energy reserve (Fig. 4A), without changes in the TCA cycle (Fig. 4B). Furthermore, there are alterations in carbohydrate, lipid and amino acid metabolism: enhanced glucose and glycogen levels (Fig. 3C) as well as altered lipid metabolism constituents, acetate and acetyl carnitine (Fig. 3D). Furthermore, there were decreased levels of succinate (Fig. 3B) however given that the succinate/fumarate ratio was unaltered (Sham 26 ± 8 vs RUPP 15 ± 5, P < 0.2), the overall TCA cycle flux appears unaltered. Despite a series of changes in metabolite levels across different metabolic compartments, there is no evidence of energetic deficit or stress as creatine reserve and PCr/ATP ratio are comparable to sham controls. Furthermore, there is no change in the total adenine nucleotide (TAN) pool as ATP, ADP and AMP levels are comparable between the groups (Fig. 3A) and no alterations in the amino acid metabolism short of aspartate (Fig. 3E). Furthermore, there is evidence that preeclampsia induced maternal cardiac hypoxia as the protein levels of HIF-1α are increased compared to the sham controls (Fig. 1B) in agreement with the altered carbohydrate pool (Fig. 3C).

**Computational modelling identifies metabolic flux adaptations in the RUPP maternal hearts.** To assess the impact of the RUPP model of preeclampsia on maternal cardiac metabolism at a systems scale, we conducted mathematical modelling using CardioNet. CardioNet has been successfully applied to identify limiting metabolic processes and estimate flux distributions. We determined flux distributions using flux balance analysis (FBA), which seeks to estimate flux rates during steady-state while optimising an objective function (see Supplementary Methods for details). The optimisation problem was to maximize ATP provision within a set of constraints defined by our experimental conditions. Maternal heart metabolic data measured by 1H NMR spectroscopy was included into the simulations to determine which metabolic flux distributions are consistent with the maternal cardiac adaptation during preeclampsia. These simulations were conducted without constraining enzymatic activities; thus, the optimisation problem was defined by experimentally determined metabolite levels. Principal component analysis (PCA) (Supplementary Fig. S3A) of estimated flux distributions clearly differentiated samples according to the presence of preeclampsia. Annotation enrichment of the observed metabolic clusters and unsupervised hierarchical cluster analysis (Supplementary Fig. S3B) demonstrate extensive metabolic flux remodelling in glycolysis and lipid metabolism resulting in maintained ATP provision in the maternal heart. In silico modelling shows that RUPP hearts require overall more nutrients to maintain ATP provision and are exposed to increased ROS stress. Preeclampsia enhances glucose uptake and increases the rate of glycolysis as the key reactions involved in glycolysis were upregulated (Fig. 6) accompanied by increased lactate efflux (Fig. 6). Thus overall, Cardionet modelling indicates increased carbohydrate use. However, carbs from glycolysis are still predicted to enter the Krebs Cycle for oxidative phosphorylation. Furthermore, in silico modelling indicates that in RUPP conditions endogenous lipid pools are utilized to provide ATP. This increases oxidation of fatty acids (hexadecenoyl-CoA, stearoyl-CoA, palmitoyl-CoA, oleoyl-CoA) derived from phospholipids and is potentially responsible for the observed increase in the production of reactive oxygen species (Fig. 6).

**Figure 1.** RUPP increases HIF1α expression in placenta and maternal hearts. RUPP leads to increase in HIF-1α protein expression in placenta (A) and maternal hearts (B). Protein lysates were extracted from placenta and heart from each rat and western blotting performed to determine the expression of HIF-1α relative to the total protein. Two group comparison was carried out using the student t test, n ≥ 5; P values < 0.05 shown in individual plots.
Figure 2. Representative $^1$H NMR spectra from heart (maternal and fetal) and placenta.
Figure 3. Metabolomic profile of RUPP model of maternal hearts. Metabolite concentrations are grouped into (A) Redox and Energetics (B) TCA cycle (C) Carbohydrate metabolism (D) Lipid metabolism (E) Amino acid metabolism. Two group comparison was carried out using the student T test (normally distributed data) or Mann-Whitney U test (non-normally distributed data: acetate, aspartate, NADH, lactate, leucine, valine, lactate, glutamine, choline) n = 5/group. TAN-total adenine nucleotide pool (AMP + ADP + ATP). PCr- phosphocreatine n ≥ 5; P values < 0.05 shown in individual plots.

Discussion
In this study we have examined the impact of surgically induced reduced perfusion to the uterus in pregnant rats on the metabolism of placenta, maternal and fetal hearts. Cardiovascular alterations particularly cardiac metabolism, have not been extensively studied in this model of preeclampsia. Reduced uterine perfusion leads to pathophysiological effects consistent with preeclampsia–increased fetal resorption, intrauterine growth restriction and increased haemodynamic load in maternal cardiovascular system resulting in increased heart rate, systolic, diastolic and mean arterial pressures resulting in cardiac hypertrophic enlargement. Furthermore, our RUPP model is characterized by impaired placental, renal and cardiac phenotype in agreement with the other studies characterizing the RUPP model. Given the well-established association between preeclampsia and increased risk of development of cardiovascular complications in the offspring, this is an important aspect in characterizing the manifestations of pre-eclampsia. Of notice, our recently published study describes the overlapping mechanisms between preeclampsia and future cardiovascular disease with angiogenesis- and inflammatory-related pathways playing a key role.

However, this is the first study that explores the maternal and fetal cardiometabolic health in the pre-clinical RUPP model of preeclampsia. Our study shows that systemic haemodynamic overload triggered by reduced uterine perfusion impacts metabolism of maternal heart and placenta. Resultant increase in HIF-1α expression corresponds to adaptive metabolic remodelling in response to RUPP. Changes observed in RUPP maternal hearts are suggestive of adaptive metabolic remodelling as we see no evidence of energetic deficit with comparable high energy phosphates. Cardiac metabolic changes manifest as a drop in redox pool (NAD/NADH ratio) and enhanced carbohydrate metabolism in terms of uptake and storage of glucose. However, whilst the myocardial lactate concentration is comparable between the groups, our in silico modelling has shown enhanced lactate efflux in keeping with previously reported increased circulating lactate levels in RUPP models. Furthermore, we have recently shown that altered glucose metabolism in pre-gestational or gestational diabetes results in increased risk of placental vascular dysfunction and malperfusion.
Our data has shown that the RUPP model of preeclampsia induces a change in maternal myocardial substrate use concurrent with the presence of cardiac hypertrophy\(^2\). We observed increased levels of acetate and acetyl carnitine, potentially indicative of increased lipid utilisation. However, acetate accumulation observed in RUPP maternal hearts could also arise as the metabolic consequence of enhanced oxidative glucose metabolism and pyruvate dehydrogenase activity\(^3\). The RUPP metabolic profile was characterized by increased ATP demand met by increased glucose utilization but also enhanced use of endogenous lipids accompanied by increased production of reactive oxygen species (ROS). We speculate that the increased oxidation of endogenous lipids is responsible for increased ROS production. The in silico profile indicates that fatty acid oxidation is only feasible if oxygen consumption can simultaneously be increased. The model predicts that if oxygen becomes limiting, this would further increase the use of glucose by maternal RUPP hearts. The drop in the NAD\(^+\)/NADH ratio is also indicative of the altered nicotinamide turnover, which has recently been shown to be an important hallmark of metabolic remodelling in cardiac pathologies\(^4\).

Expectedly, reduced uterine perfusion exhibited the strongest metabolic effect on placentae. A myriad of studies over the years have shown that the placenta is the fundamental source of fetal programming in adverse intrauterine environment and that metabolic remodelling is the incipient step in the progression to more severe forms of fetal growth restriction\(^5\). Reduced tissue perfusion normally triggers a range of responses including increased angiogenesis and erythropoiesis in order to improve O\(_2\) availability needed for cellular survival under hypoxic conditions. In both human and animal placentas, hypoxia-triggered responses result in increased density of villous capillaries and elevated secretion of angiogenic and hematopoietic factors (ie. VEGF, erythropoietin)\(^6\). However, as our previous work has shown, preeclampsia is characterized by an anti-angiogenic phenotype driven by the upregulation in FKBPL expression or increase in sFlt-1, which would disrupt this primary hypoxia defence mechanism triggered by reduced perfusion\(^7,8\).

Increased ATP levels driving an increase in the TAN pool are indicative of altered placental ATP homeostasis driven by reduced perfusion and resultant hypoxia as evidenced by increased HIF-1\(\alpha\) expression. In non-placenta tissue including hearts this would be a rare finding as ATP levels are tightly regulated (in part via the Randle cycle) to avoid energetic waste. This observation could potentially have two implications. First, RUPP
placenta with an anti-angiogenic phenotype and altered HIF-1α could lead to reduced energy demand by reducing the activity of ATP utilizers, thus reducing ATP use. This response in placental biology is broadly defined as “demand reduction” and consists of the attenuation of energy-requiring processes, non-essential to cellular survival, including gross energy demands such as fetal movement. At the tissue level the inhibition of transcription, translation and related processes is dependent on protein synthesis, such as cellular growth and proliferation. Furthermore, this interpretation would be entirely consistent with the traditional observation that hypoxia triggers adaptation to augment the ATP supply including via non-oxidative pathways. In the placenta this process has been demonstrated most clearly by an increase in glucose uptake and consumption as well as other key elements of the glycolytic metabolism. Reduction in oxidative pathways, specifically a shift towards carbohydrate metabolism of RUPP placentae, would also be supported by the accumulation of carnitine due to altered fatty acid use.

Furthermore, we also observe changes in placental choline and phosphocholine levels, indicative of altered and enhanced nutrient transport in response to restricted vascularization and perfusion. Choline is an important bioactive micronutrient often grouped with the B vitamins. Placental transport of choline from the maternal circulation is largely mediated by the choline transporter-like protein 1 (CTL1). Within the placenta, choline and its metabolites perform crucial roles in placental and foetal development, especially the development of the brain. Enhanced choline uptake from maternal circulation, which would lead to enhanced levels in the placenta, would help to maintain both essential and non-essential amino acids for fetal development as well as enhance glycogen synthesis in the placenta as the additional source of energy.

Thus, enhanced choline and its metabolite phosphocholine levels would also explain the increased glycogen content we observed in RUPP placentae. Whilst the metabolic profile of amino acids was mostly unaffected by RUPP, levels of valine were markedly reduced suggesting enhanced fetal uptake and oxidation.

Despite the series of metabolic adaptations in maternal hearts and placentae we observed in our study, these were unable to prevent intrauterine growth restrictions and fetal loss as RUPP dams had higher fetal resorption rate in agreement with both human preeclampsia and animal model outcomes. Although surviving embryos were smaller overall, there is no evidence of extensive cardiometabolic remodelling. However, whilst there may not be many metabolite levels altered in the hearts of RUPP pregnancy fetuses, there is a marked reduction in the level of the most critical metabolite, glucose. Unlike adult hearts, fetal hearts rely on glucose as the main source of ATP. Glucose is the principal energy substrate for the placenta and the fetus and is essential for normal fetal metabolism and growth. However, given that there are no alterations in fetal heart energy reserve, redox
While this study reports the response of maternal and fetal heart tissues to preeclampsia-driven stress, future studies may help to further evaluate the underlying mechanisms that regulate the effects of preeclampsia on fetal cardiac function. This should include the effects of comorbidities often present with preeclampsia such as obesity and type 2 diabetes. In our RUPP model, we demonstrate that preeclampsia leads to fetal loss, cardiac remodelling and dysfunction showing likely signs of diastolic dysfunction26. Furthermore, we demonstrate, for the first time that preeclampsia drives an adaptive metabolic remodelling axis encompassing maternal heart and placenta. However, these adaptations are unable to prevent overall intrauterine growth restriction and fetal loss in RUPP rats despite largely unaltered fetal heart metabolism. We cannot however exclude the possibility that metabolic adaptation of the maternal tissues drives enhanced fetal resorption in order to conserve substrates and O₂ for the remaining fetuses. Furthermore, placenta and maternal heart adaptations could be protecting the metabolism of the developing fetal hearts. Nevertheless, long-term consequences of this adaptive maternal cardiovascular changes need to be investigated further.

Potential metabolic mechanisms identified in this study could inform future studies intending to provide better understanding of the increased risk of cardiovascular disease in women affected by preeclampsia. This could also provide improved prevention strategies for reducing the risk of future cardiovascular complications following preeclampsia.

**Data availability**
All data supporting the results presented herein are available from the corresponding author upon reasonable request. Cardionet modelling data are provided in a Supplementary File. Database availability: Cardionet MODEL1212040000;

Received: 9 August 2021; Accepted: 31 December 2021
Published online: 21 January 2022
experiments, data analysis and interpretation. L.M. and K.B. carried out in vivo experiments, supervised C.R. and

Acknowledgements

Author contributions

D.A.- wrote and edited the manuscript, designed the study, performed \(^1\)H NMR experiments and analysis, supervised N.P. and interpreted data. N.P. helped to perform \(^1\)H NMR experiments. C.R. and K.S. performed experiments, data analysis and interpretation. L.M. and K.B. carried out in vivo experiments, supervised C.R. and

...
L.M. and performed data analysis and interpretation. A.K. performed in silico analysis (Cardionet), data interpretation and edited the manuscript. All authors contributed to manuscript editing and approved the final draft.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-05120-2.

**Correspondence** and requests for materials should be addressed to D.A.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022